{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:44:41Z","timestamp":1781840681474,"version":"3.54.5"},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,10]],"date-time":"2001-12-10T00:00:00Z","timestamp":1007942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases in Obstetrics and Gynecology"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:p><jats:italic>Objectives:<\/jats:italic> Imiquimod is an immune response modifier that has demonstrated a good efficacy and relatively low\nrecurrencerates in comparison to other genitalwart treatment modalities. The primary objective of this open\u2010label\nstudy was to evaluate the effect on sustained clearance of treated lesions and the safety of patient\u2010applied topical\nimiquimod after laser therapy of external anogenital warts.<\/jats:p><jats:p><jats:italic>Methods:<\/jats:italic> After laser treatment of visible external anogenital warts the ablated region(s) were treated with\nimiquimod 5% cream three times\/week over 12 weeks beginningwhen the wound healing process was completed,\nfollowed by a six\u2010month treatment\u2010free observation period for the assessment of sustained clearance of treated\nlesions.<\/jats:p><jats:p><jats:italic>Results:<\/jats:italic> A total of 211 male and female patients was enrolled in the study. After 12 weeks of treatment, 65.4% of\nall patients showed sustained clearance. During the treatment period, 15 patients (7.1% of 211 patients) presented\nwith recurrent warts in the treated areas, and 58 (27.5%) patients were excluded for other reasons. During\nthe six\u2010month follow\u2010up period, ten additional patients (7.3% of 138 patients) developed wart recurrences. The\napplication of imiquimod 5% cream was well tolerated. The number of patients with adverse events related to\nstudymedication declined fromthe first month of treatment until the end of the third month.Most frequently, mild\nto moderate itching, burning, pain and erythema were reported.<\/jats:p><jats:p><jats:italic>Conclusions:<\/jats:italic> After laser therapy and sufficient wound healing, administration of imiquimod 5% cream three\ntimes\/week appears to be safe and to reduce the incidence of wart recurrences.<\/jats:p>","DOI":"10.1155\/s1064744902000066","type":"journal-article","created":{"date-parts":[[2007,3,7]],"date-time":"2007-03-07T13:12:46Z","timestamp":1173273166000},"page":"79-88","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effect of Adjuvant Imiquimod 5% Cream on SustainedClearance of Anogenital Warts Following Laser Treatment"],"prefix":"10.1155","volume":"10","author":[{"given":"U. B.","family":"Hoyme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hagedorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Schneede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hopfenm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Schorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Eul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,10]]},"container-title":["Infectious Diseases in Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/idog\/2001\/567614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/S1064744902000066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T15:59:10Z","timestamp":1720022350000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/S1064744902000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,10]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1155\/S1064744902000066"],"URL":"https:\/\/doi.org\/10.1155\/s1064744902000066","archive":["Portico"],"relation":{},"ISSN":["1064-7449"],"issn-type":[{"value":"1064-7449","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12,10]]},"assertion":[{"value":"2001-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-12-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-12-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}